Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO David Ricks joined the program "First on CNBC" to discuss the pharma giant’s weight-loss drug: The company says it cut diabetes risk by 94% in a late-stage trial. Also in focus: Nvidia and the "Mag 7" post-selloff surge, earnings from the likes of Lowe's and Palo Alto Networks, another setback for Boeing, the Alaska Air-Hawaiian Airlines merger clears an antitrust hurdle.
Squawk on the Street Disclaimer
Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO David Ricks joined the program "First on CNBC" to discuss the pharma giant’s weight-loss drug: The company says it cut diabetes risk by 94% in a late-stage trial. Also in focus: Nvidia and the "Mag 7" post-selloff surge, earnings from the likes of Lowe's and Palo Alto Networks, another setback for Boeing, the Alaska Air-Hawaiian Airlines merger clears an antitrust hurdle.
Squawk on the Street Disclaimer
